Krystal Biotech
KRYS
137 hedge funds and large institutions have $1.36B invested in Krystal Biotech in 2022 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 46 increasing their positions, 52 reducing their positions, and 15 closing their positions.
137% more call options, than puts
Call options by funds: $9.2M | Put options by funds: $3.87M
27% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 15
1% more funds holding
Funds holding: 135 → 137 (+2)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0% less capital invested
Capital invested by funds: $1.37B → $1.36B (-$4.09M)
0.63% less ownership
Funds ownership: 81.7% → 81.07% (-0.63%)
12% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$14.3M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$5.76M |
| 3 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
+$5.53M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$5.15M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$4.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.08M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$7.61M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$4.66M |
| 4 |
Jennison Associates
New York
|
-$4.54M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$3.81M |
KRYS Hedge Fund Activity: Q2 2022 in Review
137 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q2 2022, worth a combined $1.36B — down 0.3% from $1.37B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new KRYS positions and 15 closed out — a net gain of 4 holders — while 46 added to existing stakes and 52 trimmed.
The largest buyer was Frazier Life Sciences Management, adding an estimated $14.3M. The largest seller was Point72 Asset Management, cutting an estimated $9.08M.
- 137 institutional investors held Krystal Biotech (KRYS) as of Q2 2022, up from 135 in Q1 2022.
- Funds reported $1.36B of Krystal Biotech stock for Q2 2022, down 0.3% quarter-over-quarter.
- 19 funds opened new Krystal Biotech positions in Q2 2022 and 15 closed out, a net change of +4 holders.
- The largest Krystal Biotech buyer in Q2 2022 was Frazier Life Sciences Management, an estimated $14.3M added.
- The largest Krystal Biotech seller in Q2 2022 was Point72 Asset Management, an estimated $9.08M sold.
Based on aggregated 13F filings for Q2 2022.